Your browser doesn't support javascript.
loading
Major Depressive Disorder in Older Patients as an Inflammatory Disorder: Implications for the Pharmacological Management of Geriatric Depression.
Forbes, Malcolm P; O'Neil, Adrienne; Lane, Melissa; Agustini, Bruno; Myles, Nick; Berk, Michael.
Afiliación
  • Forbes MP; Mental Health, Drugs and Alcohol Services, Barwon Health, Geelong, VIC, 3216, Australia. malcolm.forbes@unimelb.edu.au.
  • O'Neil A; The Institute for Mental and Physical Health and Clinical Translation (IMPACT), School of Medicine, Deakin University, Geelong, VIC, 3216, Australia. malcolm.forbes@unimelb.edu.au.
  • Lane M; Department of Psychiatry, University of Melbourne, Parkville, VIC, 3050, Australia. malcolm.forbes@unimelb.edu.au.
  • Agustini B; The Institute for Mental and Physical Health and Clinical Translation (IMPACT), School of Medicine, Deakin University, Geelong, VIC, 3216, Australia.
  • Myles N; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, 3004, Australia.
  • Berk M; The Institute for Mental and Physical Health and Clinical Translation (IMPACT), School of Medicine, Deakin University, Geelong, VIC, 3216, Australia.
Drugs Aging ; 38(6): 451-467, 2021 06.
Article en En | MEDLINE | ID: mdl-33913114
Depression is a common and highly disabling condition in older adults. It is a heterogenous disorder and there is emerging evidence of a link between inflammation and depression in older patients, with a possible inflammatory subtype of depression. Persistent low-level inflammation, from several sources including psychological distress and chronic disease, can disrupt monoaminergic and glutaminergic systems to create dysfunctional brain networks. Despite the evidence for the role of inflammation in depression, there is insufficient evidence to recommend use of any putative anti-inflammatory agent in the treatment of depression in older adults at this stage. Further characterisation of markers of inflammation and stratification of participants with elevated rates of inflammatory markers in treatment trials is needed.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trastorno Depresivo Mayor Límite: Aged / Humans Idioma: En Revista: Drugs Aging Asunto de la revista: GERIATRIA / TERAPIA POR MEDICAMENTOS Año: 2021 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Nueva Zelanda
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trastorno Depresivo Mayor Límite: Aged / Humans Idioma: En Revista: Drugs Aging Asunto de la revista: GERIATRIA / TERAPIA POR MEDICAMENTOS Año: 2021 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Nueva Zelanda